Summary
Prima BioMed Ltd. (Prima BioMed) is a biotechnology company which develops a wide range of immunocellular therapeutic products for the treatment of cancer. Its pipeline products are based on LAG-3 immune control mechanism which is involved in the regulation of the T cell immune response. The company’s lead product CVac ovarian cancer vaccine, is a maintainence therapy vaccine which is administered post-surgery and post-chemotherapy to delay relapse and control metastases. It has various collaborations with Eddingpharm, GlaxoSmithKline, Novartis and WuXi AppTec. The company has a manufacturing facility in Leipzig, Germany. Prima BioMed is headquartered in Sydney, New South Wales, Australia.
Prima BioMed Ltd. (PRR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Prima BioMed Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Prima Biomed Forms Partnership with Database Integrations 12
Immutep Enters Into Development Agreement With Eddingpharm For ImmuFact IMP321 13
Prima BioMed Enters into Agreement with University of New South Wales and University of Queensland 15
Prima BioMed Enters Into Co-Development Agreement With Fraunhofer Institute 17
Licensing Agreements 18
Prima BioMed Enters Into Licensing Agreement With Neopharm For CVac 18
Immutep Enters Into Licensing Agreement With GlaxoSmithKline For ImmuTune IMP731 20
Equity Offering 22
Prima BioMed Raises USD1.4 Million in Private Placement of Shares 22
Prima BioMed Raises USD1.14 Million in Private Placement of Shares 23
Prima BioMed Raises USD7.5 Million in Rights Offering of Shares 25
Prima BioMed Raises USD0.19 Million in Private Placement of Shares upon Exercise of Warrants 26
Prima BioMed Plans to Raise USD4 Million in Rights Offering of Shares 27
Prima BioMed to Raise USD1 Million in Private Placement of Shares 28
Prima BioMed Files Registration Statement For Public Offering Of American Depositary Shares For US$60 Million 29
Prima BioMed Completes Second Tranche Of Private Placement Of Shares For US$3 Million 30
Prima BioMed Completes Private Placement Of Shares For US$1.3 Million 32
Prima BioMed Completes Private Placement Of Shares For US$1 Million 33
Prima BioMed Completes Rights Offering Of Shares For US$5.2 Million 34
Prima BioMed Completes Rights Issue Of US$21 Million 35
Prima BioMed Completes Private Placement Of US$22 Million 37
Prima BioMed Completes Private Placement Of US$2.25 Million 38
Debt Offering 40
Prima BioMed to Raise USD11 Million in Private Placement of 3% Notes 40
Acquisition 41
Prima BioMed Acquires Immutep for USD25 Million 41
Prima BioMed Ltd. - Key Competitors 43
Key Employees 44
Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46
List of Tables
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Key Facts, 2015 1
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Prima BioMed Ltd., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Prima BioMed Ltd., Deals By Therapy Area, 2010 to YTD 2016 9
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Prima Biomed Forms Partnership with Database Integrations 12
Immutep Enters Into Development Agreement With Eddingpharm For ImmuFact IMP321 13
Prima BioMed Enters into Agreement with University of New South Wales and University of Queensland 15
Prima BioMed Enters Into Co-Development Agreement With Fraunhofer Institute 17
Prima BioMed Enters Into Licensing Agreement With Neopharm For CVac 18
Immutep Enters Into Licensing Agreement With GlaxoSmithKline For ImmuTune IMP731 20
Prima BioMed Raises USD1.4 Million in Private Placement of Shares 22
Prima BioMed Raises USD1.14 Million in Private Placement of Shares 23
Prima BioMed Raises USD7.5 Million in Rights Offering of Shares 25
Prima BioMed Raises USD0.19 Million in Private Placement of Shares upon Exercise of Warrants 26
Prima BioMed Plans to Raise USD4 Million in Rights Offering of Shares 27
Prima BioMed to Raise USD1 Million in Private Placement of Shares 28
Prima BioMed Files Registration Statement For Public Offering Of American Depositary Shares For US$60 Million 29
Prima BioMed Completes Second Tranche Of Private Placement Of Shares For US$3 Million 30
Prima BioMed Completes Private Placement Of Shares For US$1.3 Million 32
Prima BioMed Completes Private Placement Of Shares For US$1 Million 33
Prima BioMed Completes Rights Offering Of Shares For US$5.2 Million 34
Prima BioMed Completes Rights Issue Of US$21 Million 35
Prima BioMed Completes Private Placement Of US$22 Million 37
Prima BioMed Completes Private Placement Of US$2.25 Million 38
Prima BioMed to Raise USD11 Million in Private Placement of 3% Notes 40
Prima BioMed Acquires Immutep for USD25 Million 41
Prima BioMed Ltd., Key Competitors 43
Prima BioMed Ltd., Key Employees 44
Prima BioMed Ltd., Subsidiaries 45
List of Figures
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Prima BioMed Ltd., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
